Enzalutamide and other ARPIs are key in treating metastatic prostate cancer by blocking androgen receptors, improving patient survival rates.
Comparing ARPIs in Prostate Cancer Treatment
With no head-to-head trials for ARPIs, physicians use methods like MAIC to indirectly compare efficacy and safety, guiding treatment decisions.
Without head-to-head trials, doctors balance MAIC efficacy data with factors like cost and safety to choose the best ARPI for each patient.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Clears Pen Device for Interferon Therapy in Polycythemia Vera
2
FDA Rejects Edotreotide PET Imaging Kit Over Manufacturing Concerns
3
Deep Responses Support Push for CAR T-Cell Therapy in AL Amyloidosis
4
Phase 3 TRIDENT Trial Misses Survival End Point in Glioblastoma
5